Vercin S Ephrem, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 80 Highland St, Laconia, NH 03246 Phone: 603-524-3211 |
Heidi-anne M Hanson, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: Lrgh Hospitalist Program, Laconia, NH 03246 Phone: 603-934-2060 Fax: 603-737-6713 |
Alfonsine T Mofor, APRN Hospitalist Medicare: Medicare Enrolled Practice Location: 80 Highland St, Laconia, NH 03246 Phone: 603-524-3211 Fax: 603-737-6713 |
News Archive
Facial pain. Nasal congestion. Postnasal drip. Fatigue. These are hallmark signs of chronic sinusitis, a swelling of tissue in the nasal and sinus cavity. The illness strikes millions of Americans each year and is one of the top five reasons patients visit their primary care doctor. Treating sinusitis is difficult in part because it's often not known if the cause is viral or bacterial. Unfortunately little information on the subject is available to internists says a new study by a Georgetown University Medical Center (GUMC) internist.
Great Lakes NeuroTechnologies announced today that they received TGA approval to market Kinesia technology in Australia. The Kinesiaâ„¢ product line includes patient-worn motion sensors and a tablet computer to quantitatively assess tremor, bradykinesia, and dyskinesia associated with Parkinson's disease and in response to treatments.
The Association of Rehabilitation Nurses (ARN) presented Susan Krinsky RN CRRN CCM with the 2013 ARN Staff Nurse Role Award. Krinsky received her award at the 39th Annual ARN Annual Educational Conference, held October 2-5 in Charlotte, NC.
Metabolic diseases - in particular the increasingly prevalent type 2 diabetes - are caused by a complex interaction between genetic disposition and unfavorable lifestyle, above all unbalanced diet and too little physical exercise.
Labopharm Inc. today announced that it has been informed by Angelini, the manufacturer of the active pharmaceutical ingredient (API) for the Company's novel trazodone formulation, that it has received a letter from the U.S. Food and Drug Administration (FDA) stating that Angelini has appropriately addressed all deficiencies cited by the FDA following its inspection of the manufacturing facility in June and July of this year.
› Verified 5 days ago